The Production Process of (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide

The (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide is a compound that is used in the treatment of various neurological disorders, including Parkinson's disease.
The compound is synthesized through a complex series of chemical reactions that require the use of specialized equipment and techniques.
In this article, we will take a closer look at the production process of (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide.

Step 1: Synthesis of the starting material
The first step in the production of (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide is the synthesis of the starting material.
This involves the synthesis of a compound known as 7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-one, which is then converted to the target compound through a series of chemical reactions.

Step 2: Synthesis of the target compound
Once the starting material has been synthesized, the next step is to synthesize the target compound (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide.
This involves a series of chemical reactions, including the condensation of the starting material with N-({4-[(4-nitrophenyl)methyl]phenyl}amino)-4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazoline-6-carboxamide, and the reduction of the resulting compound to produce the desired product.

Step 3: Purification and isolation of the target compound
After the target compound has been synthesized, it must be purified and isolated from any impurities that may be present.
This involves the use of specialized equipment, such as chromatography columns and recrystallization tanks, to separate the target compound from any impurities.

Step 4: Characterization of the target compound
Once the target compound has been purified and isolated, it must be characterized to ensure that it meets the desired specifications.
This involves the use of various techniques, such as spectroscopy and mass spectrometry, to determine the chemical properties of the compound.

Step 5: Packaging and distribution
Once the target compound has been characterized, it is packaged in appropriate containers for distribution to pharmaceutical companies and clinics.
The packaging must meet all relevant regulations and standards to ensure the safe and effective storage and use of the compound.

In conclusion, the production process of (S,E)-4-(dimethylamino)-N-(4-oxo-7-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroquinazolin-6-yl)but-2-enamide involves several complex chemical reactions that require specialized equipment and techniques.
The compound is synthesized from a starting material and purified to ensure that it meets the desired specifications.
It is then packaged and distributed to pharmaceutical companies and clinics for use in the treatment of various neurological disorders.